What is it about?

Peter Libby MD, reflects on CANTOS and a new era of personalised medicine

Featured Image

Why is it important?

For many basic science labs around the world the hotly-anticipated findings of the CANTOS trial delivered at the ESC Congress in 2017 were welcomed as an affirmation of years, if not decades of work on inflammation. It was an important moment for Peter Libby MD, Mallinckrodt Professor of Medicine at Harvard Medical School and long-time Chief of Cardiovascular Medicine at Brigham and Women’s Hospital in Boston, Massachusetts, USA. Investigators in his own lab have been engaged in inflammation research for many years.


An important perspective from a crucial investigator

Judith Ozkan

Read the Original

This page is a summary of: Peter Libby MD and CANTOS, European Heart Journal, May 2018, Oxford University Press (OUP), DOI: 10.1093/eurheartj/ehy177.
You can read the full text:




The following have contributed to this page